ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Mirati Therapeutics Inc. (MRTX) Report Updated: Apr 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Mirati Therapeutics Inc. (MRTX)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: ANAC, INSY, PRTA, BCRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

Mirati Therapeutics Inc.© quotemedia

Company Profile

Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.

Recent News: Mirati Therapeutics Inc.